These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9916097)

  • 1. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis.
    Cárdenas-Freytag L; Cheng E; Mayeux P; Domer JE; Clements JD
    Infect Immun; 1999 Feb; 67(2):826-33. PubMed ID: 9916097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial protection against experimental vaginal candidiasis after mucosal vaccination with heat-killed Candida albicans and the mucosal adjuvant LT(R192G).
    Cárdenas-Freytag L; Steele C; Wormley FL; Cheng E; Clements JD; Fidel PL
    Med Mycol; 2002 Jun; 40(3):291-9. PubMed ID: 12146759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
    Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
    PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
    Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
    Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G).
    Smiley KL; McNeal MM; Basu M; Choi AH; Clements JD; Ward RL
    J Virol; 2007 Apr; 81(8):3740-8. PubMed ID: 17251301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.
    Chong C; Friberg M; Clements JD
    Vaccine; 1998 Apr; 16(7):732-40. PubMed ID: 9562694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.
    Ryan ET; Crean TI; John M; Butterton JR; Clements JD; Calderwood SB
    Infect Immun; 1999 Apr; 67(4):1694-701. PubMed ID: 10085006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates.
    VanCott JL; Prada AE; McNeal MM; Stone SC; Basu M; Huffer B; Smiley KL; Shao M; Bean JA; Clements JD; Choi AH; Ward RL
    J Virol; 2006 May; 80(10):4949-61. PubMed ID: 16641286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
    Byrd W; Boedeker EC
    Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.
    Sjökvist Ottsjö L; Flach CF; Clements J; Holmgren J; Raghavan S
    Infect Immun; 2013 May; 81(5):1532-40. PubMed ID: 23439305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
    Lu X; Clements JD; Katz JM
    Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.
    Albert MJ; Haridas S; Ebenezer M; Raghupathy R; Khan I
    PLoS One; 2015; 10(11):e0142090. PubMed ID: 26540197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.
    O'Neal CM; Clements JD; Estes MK; Conner ME
    J Virol; 1998 Apr; 72(4):3390-3. PubMed ID: 9525668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-antigen fusion protein vaccination induces protective immunity against
    Jia K; Zhang Y; Jiang M; Cui M; Wang J; Zhang J; Wang H; Zhao H; Li M; Zou Q; Zeng H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406065. PubMed ID: 39327639
    [No Abstract]   [Full Text] [Related]  

  • 17. Ginsenoside Rd induces protective anti-Candida albicans antibody through immunological adjuvant activity.
    Han Y; Rhew KY
    Int Immunopharmacol; 2013 Nov; 17(3):651-7. PubMed ID: 24007781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.
    Kotloff KL; Sztein MB; Wasserman SS; Losonsky GA; DiLorenzo SC; Walker RI
    Infect Immun; 2001 Jun; 69(6):3581-90. PubMed ID: 11349017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.
    Weltzin R; Guy B; Thomas WD; Giannasca PJ; Monath TP
    Infect Immun; 2000 May; 68(5):2775-82. PubMed ID: 10768972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.